by Isogenica Webmaster | Nov 2026 | nanobodies
EgA1 is a camelid-derived VHH that recognises a challenging epitope near the interface of EGFR domains II and III. EgA1 provides a structural and functional example of how VHHs can target challenging epitopes on cancer-relevant receptors. Target: Epidermal...
by Isogenica Webmaster | Oct 2026 | nanobodies
NM-02, an anti-HER2 single-domain antibody NM-02 demonstrates how VHHs can function as molecular delivery vehicles, rather than simply as standalone therapeutic binders. Target: Human Epidermal Growth Factor Receptor 2 (HER2) Why it matters: NM-02 is an...
by Isogenica Webmaster | Sep 2026 | nanobodies
The BCMA VHH pair behind Carvykti An elegant example of how VHHs can be engineered into advanced therapies. Target: B-cell maturation antigen (BCMA), a cell surface protein highly expressed on malignant plasma cells in multiple myeloma. Why it matters: Multiple...
by Isogenica Webmaster | Sep 2026 | nanobodies
Nb80: a VHH that captures GPCR in its active state Target:β2-adrenergic receptor (β2AR), an important G protein-coupled receptor (GPCR) Why it matters: Nb80 helped solve a long-standing problem in structural biology: capturing a GPCR in its active state.GPCRs are...
